sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Latanoprost

Medicine · Prostaglandin Analog

Latanoprost

Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Do not take if
Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product.

Side effects, and when to stop

The following adverse reactions were reported in postmarketing experience and are discussed in greater detail in other sections of the label:

  • Iris pigmentation changes
  • Eyelid skin darkening
  • Eyelash changes (increased length, thickness, pigmentation, and number of lashes)
  • Intraocular inflammation (iritis/uveitis)
  • Macular edema, including cystoid macular edema

Who should not take it

Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product.

2 dosage and administration

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal. The dosage of latanoprost ophthalmic solution should not exceed once daily; the combined use of two or more prostaglandins, or prostaglandin analogs including latanoprost ophthalmic solution is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP. Reduction of the IOP starts approximately 3 to 4 hours after administration and the maximum effect is reached after 8 to 12 hours. Latanoprost ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower IOP. In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost ophthalmic solution. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. Contact lenses should be removed prior to the administration of latanoprost ophthalmic solution, and may be reinserted 15 minutes after administration.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Latanoprost; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/latanoprost

APA 7th

sofidex. (2026, August 3). Latanoprost. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/latanoprost

AMA 11th

Latanoprost. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/latanoprost

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.